The SOLAR-STAGE trial focuses on the diagnostic performance of 64Cu-PSMA-I&T in men recently diagnosed with unfavorable intermediate-, high-, or very-high-risk prostate cancer and those who plan on undergoing radical prostatectomy and pelvic lymph node dissection. This evidence concerns the gene FOLH1 and prostate cancer.